15963-40-3

Usage

Uses

Used in Fragrance Industry:
Cyclobutanecarboxylic acid, 3-methylene-, methyl ester (6CI,8CI,9CI) is used as a fragrance ingredient for its fruity scent, contributing to the production of perfumes and scented products.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, Cyclobutanecarboxylic acid, 3-methylene-, methyl ester (6CI,8CI,9CI) is utilized in the manufacturing process of various medications, playing a crucial role in the development of new drugs.
Used in Food Industry:
As a flavoring agent, Cyclobutanecarboxylic acid, 3-methylene-, methyl ester (6CI,8CI,9CI) enhances the taste of food products, providing a fruity flavor profile to various consumables.
Safety Precautions:
It is essential to handle Cyclobutanecarboxylic acid, 3-methylene-, methyl ester (6CI,8CI,9CI) with care, as it can be harmful if ingested, inhaled, or comes in contact with the skin or eyes. Proper safety measures should be taken to minimize potential risks during its use in various applications.

Upstream product

• 463-49-0 1,2-propanediene 
• 292638-85-8 acrylic acid methyl ester 
• 186581-53-3 diazomethane 
• 15760-35-7 3-methylenecyclobutanecarbonitrile 
• 10555-42-7 3-Brommethyl-cyclobutan-1-carbonsaeure 
• 15760-36-8 3-methylenecyclobutane-1-carboxylic acid 
• 89892-95-5 3-Brommethyl-cyclobutancarbonsaeure-methylester 
• 408326-43-2 trans-3-Methoxymethyl-cyclobutan-carbonsaeure-⁽¹⁾ 
• 5164-23-8 3-Methoxymethyl-cyclobutan-dicarbonsaeure-(1,1) 
• 5164-22-7 3-Methoxymethyl-cyclobutan-dicarbonsaeure-(1,1)-diaethylester 
• 67-56-1 methanol 
• 77-78-1 dimethyl sulfate 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 74-88-4 methyl iodide 

Downstream Products

• 578715-80-7 methyl trans-1-oxaspiro[2.3]hexane-5-carboxylate 
• 578715-81-8 methyl cis-1-oxaspiro[2.3]hexane-5-carboxylate 
• 10555-46-1 3-methylenecyclobutylmethyl bromide 
• 10555-42-7 3-Brommethyl-cyclobutan-1-carbonsaeure 
• 89941-55-9 methyl 3-(hydroxymethyl)cyclobutane-1-carboxylate 
• 1273567-26-2 spiro[2.3]hexane-5-carboxylic acid 
• 10555-45-0 (3-methylenecyclobutyl)methanol 

Relevant academic research and scientific papers

Process for preparing 3 - methylene cyclobutyl derivative

The invention provides a preparation method of 3 - methylene cyclobutyl derivatives, and uses propylene derivatives. Through screening of technological conditions such as polymerization inhibitor, reaction solvent and the like, the problem that propylene derivative polymerization blocks the reaction channel is solved while the product conversion rate is ensured.

ROR-GAMMA INHIBITORS

The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.

1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS

A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS

A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS

The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.

IRAK4 INHIBITING AGENTS

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.

DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS

The present disclosure is based, in part, on the discovery that disclosed compounds can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.

Hydroxypurine compound and use thereof

The invention discloses a hydroxypurine compound and a use of the hydroxypurine compound as a PDE2 or TNFa inhibitor and concretely discloses a compound shown in the formula (I) and its tautomer or pharmaceutically acceptable salt.

COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY

The present disclosure features compounds such as those having the Formulae (Ila), (lIb), (lIc), (Ild), (IlIa), and (Illb), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (Ila), (lIb), (lIc), (lId), (IlIa), or (Illb).

OXAZOLIDINONE HYDROXAMIC ACID COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

This invention pertains generally to treating bacterial infections using organic compounds of Formula I. In certain aspects, the invention pertains to treating infections caused by Gram-negative bacteria. (I) wherein X, Y, R1, R2, R3, R4 and R5 and defined herein.